The page you were trying to access is not available. You may have accessed this page via an outdated link, or typed in the URL incorrectly. You may find what you're looking for by searching this site or using the navigation.
The link you have selected will take you to Genentech Clinical Trials, a different site also maintained by Genentech Medical Affairs.
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?
Ab: antibody
AE: adverse event
ASTCT: American Society for Transplantation and Cellular Therapy
CR: complete response
CRS: cytokine release syndrome
CT: computed tomography
CTCAE: Common Terminology Criteria for Adverse Events
DoR: duration of response
ECOG PS: Eastern Cooperative Oncology Group performance status
FL: follicular lymphoma
ICANS: immune effector cell-associated neurotoxicity syndrome
IRF: independent review facility
IV: intravenous
IQR: interquartile range
NCI CTCAE: National Center Institute Common Terminology Criteria for Adverse Events
NHL: non-Hodgkin lymphoma
ORR: objective response rate
PET: positron emission tomography
PFS: progression-free survival
PR: partial response
R/R: relapsed/refractory
SAE: serious adverse event
SD: stable disease
USPI: United States Prescribing Information
UTI: urinary tract infection
ABC: activated B-cell–like subtype
BICR: blinded independent central review
CI: confidence interval
CNS: central nervous system
CR: complete response
DLBCL: diffuse large B-cell lymphoma
ECOG PS: Eastern Cooperative Oncology Group performance status
EFSefficacy: event-free survival for efficacy causes (time from randomization to the earliest occurrence of disease progression/relapse, death due to any cause, initiation of any non-protocol specified anti-lymphoma treatment, or biopsy-confirmed residual disease after treatment completion)
EOT: end of treatment
GCB: germinal-center B-cell–like subtype
HGBL: high-grade B-cell lymphoma
HHV8: human herpesvirus 8
HR: hazard ratio
INV: investigator
IPI: International Prognostic Index
ITT: intention-to-treat
LYSA: Lymphoma Study Association
NE: not evaluable
NOS: not otherwise specified
OS: overall survival
PET-CT: positron emission tomography and computed tomography
PFS: progression-free survival
Pola-R-CHP: polatuzumab plus rituximab, cyclophosphamide, doxorubicin, prednisone
R: randomization
R-CHOP: rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone
R-CHP: rituximab plus cyclophosphamide, doxorubicin, prednisone
USPI: United States Prescribing Information
DBPCFC: Double-blind, placebo-controlled food challenge
FDA: Food and Drug Administration
ICH: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
IgE: Immunoglobulin E
NIH: National Institutes of Health
OIT: Oral immunotherapy
OLE: Open-label extension
R: Randomized
CD19: Cluster of differentiation 19
CD20: Cluster of differentiation 20
CDC: Centers for Disease Control and Prevention
COVID-19: Coronavirus disease of 2019
DMT: Disease-modifying therapy
ECTRIMS: European Committee for Treatment and Research in Multiple Sclerosis
EMA: European Medicines Association
FDA: Food and Drug Administration
IgG1: Immunoglobulin G1
LMP: Last menstrual period
mAb: Monoclonal antibody
MCA: Major congenital anomalies
MS: Multiple sclerosis
OCR: OCREVUS (ocrelizumab)
RID: Relative infant dose
UCSF: University of California San Francisco
URTI: Upper respiratory tract infection
UTI: Urinary tract infection
ASTCT: American Society for Transplantation and Cellular Therapy
CD20: Cluster of differentiation 20
CR: Complete response
CRS: Cytokine release syndrome
CT: Computed tomography
CTCAE: Common Terminology Criteria for Adverse Events
DLBCL: Diffuse large B-cell lymphoma
DoCR: Duration of complete response
DoR: Duration of response
ECOG PS: Eastern Cooperative Oncology Group performance status
FL: Follicular lymphoma
HGBCL: High-grade B-cell lymphoma
ICANS: Immune effector cell-associated neurotoxicity syndrome
IRC: Independent Review Committee
NOS: Not otherwise specified
ORR: Objective response rate
PET: Positron emission tomography
PMBCL: Primary mediastinal B-cell lymphoma
AE: Adverse event
Ang2: Angiopoietin-2
ASTCT: American Society for Transplantation and Cellular Therapy
ATG: Anti-thymocyte globulin
CAR: Chimeric antigen receptor
CARTOX: CAR T-cell Therapy-Associated Toxicity
CD3: Cluster of differentiation 3
CPAP: Continuous positive airway pressure
CRP: C-reactive protein
CRS: Cytokine release syndrome
CTCAE: Common Terminology Criteria for Adverse Events
DIC: Disseminated intravascular coagulation
HLH: Hemophagocytic lymphohistiocytosis
ICANS: Immune effector cell–associated neurotoxicity syndrome
ICU: Intensive care unit
IFN-γ: Interferon-gamma
IL: Interleukin
INR: International normalized ratio
IRR: Infusion-related reaction
MAS: Macrophage activation syndrome
MSKCC: Memorial Sloan Kettering Cancer Center
NO: Nitric oxide
PTT: Partial thromboplastin time
TNF-α: Tumor necrosis factor alpha
VWF: von Wilebrand factor
CD3: Cluster of differentiation 3
TCR: T-cell receptor
CD4: Cluster of differentiation 4
CD8: Cluster of differentiation 8
CD226: Cluster of differentiation 226
Ig: Immunoglobulin
ITIM: Immunoreceptor tyrosine-based inhibitory motif
MHC: Major histocompatibility complex
NK: Natural killer
PD-1: Programmed cell death protein 1
PD-L1: Programmed death-ligand 1
PVR: Poliovirus receptor
TIGIT: T-cell immunoreceptor with Ig and ITIM domains
ARR: Annualized Relapse Rate
ART: Assisted Reproductive Technology
CI: Confidence Interval
DMT: Disease-modifying therapy
EDSS: Expanded Disability Status Scale
MS: Multiple Sclerosis
T: Trimester
OR: Odds ratio
OB/Gyn: Obstetrics and Gynecology
AAAAI: American Academy of Allergy Asthma & Immunology
DMT: Disease-modifying therapy
HCP: Health Care Provider
Ig: Immunoglobulin
LLN: Lower limit of normal
MS: Multiple Sclerosis
NK: Natural killer
FAERS: FDA Adverse Event Reporting System
FDA: US Food and Drug Administration
Ig: Immunoglobulin
LMP: last menstrual cycle
MCA: major congenital anomalies
MS: Multiple sclerosis
OCR: OCREVUS (ocrelizumab)
PML: progressive multifocal leukoencephalopathy
PPMS: Primary progressive multiple sclerosis
RMS: Relapsing multiple sclerosis
The link you have selected will take you to a separate website not owned or controlled by Genentech. Genentech does not recommend, endorse, or make any representation regarding the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.